К содержанию
Dr. Tara EinullaevaMedical oncologist

Cancer glossary

NGS panel in cancer care: what it is and how to read the report

What an NGS panel is in cancer: how it differs from PCR, which tumors ESMO recommends it for, and how to read a report listing mutations, MSI and TMB.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026

In short

NGS (next-generation sequencing) is a method that checks dozens or hundreds of tumor genes in a single test. The panel looks for changes that targeted drugs or immunotherapy act on, and it uses less tissue than testing one gene after another.

How it appears in your report

An NGS report is usually longer than a standard pathology report. Typical parts:

  • ‘EGFR p.L858R mutation detected, variant allele frequency 23%’ — the change itself and the share of DNA molecules carrying it.
  • ‘EML4-ALK gene fusion’ — a rearrangement that targeted drugs act on.
  • ‘MSS; TMB 4 mut/Mb’ — microsatellite instability status and tumor mutational burden.
  • ‘Variants of uncertain significance’ — changes whose meaning is not yet clear.
  • ‘Tumor cell content of the sample: 30%’ — this affects how reliable the result is.

What it means

ESMO recommends routine tumor NGS for these metastatic cancers:

Year of recommendation Cancers
2020 non-squamous non-small cell lung cancer, prostate cancer, ovarian cancer, cholangiocarcinoma
2024 (added) HR-positive HER2-negative breast cancer, GIST, sarcoma, thyroid cancer, cancer of unknown primary

ESMO also lists ‘tumor-agnostic’ targets that matter wherever the cancer started: NTRK, RET and FGFR fusions, BRAF V600E, MSI-H and high TMB. In colorectal cancer, NGS can be used instead of PCR.

Does it affect treatment

It can. A finding such as EGFR or ALK changes first-line treatment; BRCA in the tumor is a reason to discuss PARP inhibitors and inherited testing. But if there is no target, or the matching drug is not available, the report may not change the plan. ESMO advises tumor-agnostic testing where the matching drugs are accessible. Your treating doctor decides which findings matter for you.

Questions to ask your doctor

  • Which genes were on the panel — DNA, RNA or both?
  • Which of the findings matter for my treatment?
  • Do any of them mean my relatives should be tested?

More in the article on mutations in lung cancer. If you have an NGS report, I can go through it with you in a consultation.

Sources

  1. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers — ESMO, 2020
  2. When to perform next-generation sequencing test in patients with cancer? ESMO updates its recommendations — ESMO, 2024

Watch me explain this on video

Short videos on my Instagram (in Russian)

FAQ

Related terms

This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.

Related articles

All blog articles